Trial · NCT01943851
Results by group1,155
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,155
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 5 mg QD | Non-serious AEs | 1 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 10 mg QD | Non-serious AEs | 1 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 20 mg QD | Non-serious AEs | 1 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 30 mg QD MM | Non-serious AEs | 5 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 40 mg QD | Non-serious AEs | 1 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 40 mg QD MM | Non-serious AEs | 4 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 60 mg QD AML | Non-serious AEs | 8 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 60 mg QD NHL | Non-serious AEs | 18 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 60 mg QD MM | Non-serious AEs | 3 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 75 mg QD AML | Non-serious AEs | 8 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 80 mg QD | Non-serious AEs | 1 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 80 mg QD AML | Non-serious AEs | 7 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 80 mg QD NHL | Non-serious AEs | 7 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 100 mg QD AML | Non-serious AEs | 16 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 120 mg QD AML | Non-serious AEs | 6 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 5 mg QD | SAEs | 1 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 10 mg QD | SAEs | 0 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 20 mg QD | SAEs | 0 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 30 mg QD MM | SAEs | 4 | Participants | |
| Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) | Part 1: GSK525762 40 mg QD | SAEs | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01943851/results